Results 111 to 120 of about 2,423,946 (178)

ROC analysis of serum anti-PLA2R antibodies between the remission and non-remission groups at initial diagnosis.

(A) ROC curve of serum anti-PLA2R-IgG and anti-PLA2R-IgG4 between the remission and non-remission groups. (B)ROC curve of serum eGFR+ anti-CTLD678 IgG4+ urinary protein between the remission and non-remission groups.
Yuan Qin (260617), Zhigang Hu (477325), Xiumei Zhou (126818), Qingqing Wu (1969732), Xue Yang (144876), Bo Lin (116835), Zijian Huang (10776416), Xiaobin Liu (344083), Liang Wang (23021), Ting Li (117885), Jing Xue (170229), Leting Zhou (12062753), Biao Huang (215504), Huiming Sheng (485213)   +13 more
core   +1 more source

Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study. [PDF]

BMC Nephrol
Huang Y, Meng X, Wu S, Miao X, Qin L, Zhang K, Sun J, Wang J.   +7 more
europepmc   +1 more source

B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China. [PDF]

Front Immunol
Xu Y, Wang L, Jiang C, Sun D, Yang M, Liu J, Liu X, Wan C, Liu C, Zhang B, Bi G, Chen L, Zhang L, Lu G, Zhang L, Zhou H, Zhang X, Zhou G, Lu F, Zhang C, Sun B, Zeng M, Bian S, Zhang L, Wang N, Shen L, Yuan Y, Xing C, Mao H.   +28 more
europepmc   +1 more source

Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China. [PDF]

Med Sci Monit, 2019
Guo N, Cao Y, Dai H, Yuan L, Shi L, Zhang Y.   +5 more
europepmc   +1 more source

Hispanic Patient with Breast Cancer and Secondary Membranous Nephropathy with rare positive anti-PLA2R autoantibodies which changes the management. [PDF]

Introduction 10% of membranous nephropathy (MN) cases are linked to solid organ tumors, most commonly in Caucasians. Positive anti phospholipase-A2-receptor (PLA2R) autoantibodies are found in 75% of patients with primary MN but are rare in secondary MN ...
Mondreti, Kalyana, Uha, Yalala, Suarez Parraga, Andres, Gavilanes, Diana   +3 more
core  

Anti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy

Brazilian Journal of Nephrology
Gianna Mastroianni-Kirsztajn, Michelle T. Passos Riguetti, Juliana Mansur Siliano   +2 more
openaire   +3 more sources

Correlation of Glomerular MBL Deposition with the Clinicopathology and Prognosis of Idiopathic Membranous Nephropathy: A PLA2R Subgroup Analysis. [PDF]

Int J Gen Med
Pan Y, Zhao Y, Wu X, Chen B, Lu M, Shao D, Liu L, Chen W.   +7 more
europepmc   +1 more source

Anti-PLA2R autoantibodies induce complement activation via IgG subclass-dependent epitope pairings in membranous nephropathy. [PDF]

J Clin Invest
Wu TY, Tu KH, Seifert L, Lin KW, Shih HP, Lo YF, Peng JJ, Zahner G, Kretz O, Lin YN, Kang CX, Ding JY, Tu YR, Ma LY, Chuang YT, Lo CC, Tsai YH, Yang CW, Tomas NM, Ku CL.   +19 more
europepmc   +1 more source

Can we manage without biopsy in membranous nephropathy with positive anti-PLA2R antibodies?

Nefrología (English Edition), 2019
Lara Ruiz Martínez, Gema Fernández Fresnedo, Emilio Rodrigo, Milagros Heras   +3 more
openaire   +1 more source

Rituximab Outcomes and Predictors of Treatment Failure in Primary Membranous Nephropathy: A Retrospective Cohort Study. [PDF]

J Clin Med
Güllülü Boz SE, Hunutlu FÇ, Çelik E, Çalışır Aİ, Soyak Kabaca H, Gül CB, Yıldız A, Ersoy A, Güllülü M, Oruç A.   +9 more
europepmc   +1 more source